CRISPR Market - Strategic Insights and Forecasts (2026-2031)

The CRISPR market is forecast to reach USD 10.6 billion by 2031, growing from USD 6.2 billion in 2026. This represents a robust Compound Annual Growth Rate (CAGR) of 11.3% over the forecast period, driven by the structural demand for high-precision genomic intervention tools and a fundamental shift towards curative, one-time interventions.

Pharmaceutical and biotechnology companies constitute the primary demand source for the CRISPR market. This is driven by the transition of multiple CRISPR candidates into Phase 3 clinical trials and the subsequent requirement for commercial-scale manufacturing capacity, necessitating a robust evolution in Chemistry, Manufacturing, and Controls (CMC) processes for therapeutic-grade components.

North America maintains the largest market share in the CRISPR market. Its leadership is attributed to a concentrated infrastructure of specialized genomic research centers and the presence of early-mover therapeutic developers, which centralize global demand for high-fidelity gene-editing kits and advanced CRISPR platforms.

There is a clear technological shift occurring from standard double-strand break (DSB) methods toward more precise modalities such as base editing and CRISPR-mediated RNA editing. These advanced technologies are preferred because they reduce the risk of unintended chromosomal rearrangements, thereby expanding the technology's therapeutic ceiling and enhancing safety profiles.

The historic approval of exagamglogene autotemcel (CASGEVY) by the US FDA and the UK MHRA has established a blueprint for regulatory pathways, significantly de-risking the legal and safety landscape for investors. This regulatory clarity directly increases demand for CRISPR-Cas9 platforms and facilitates sustained public and private capital inflows into genomic infrastructure, also influenced by regulatory differentiation for gene-edited crops.

The agricultural sector is increasingly leveraging CRISPR as part of a 'sustainability transition,' focusing on developing climate-resilient and high-nutrient produce. Furthermore, CRISPR is viewed as a sovereign technological asset within 'bioeconomy' strategies of major powers, contributing to healthcare security and agricultural independence.